A preview of Luigi Negri’s upcoming Springer book on de-risking medical technology investments.

𝗗𝗲-𝗿𝗶𝘀𝗸𝗶𝗻𝗴 𝗺𝗲𝗮𝗻𝘀 𝘁𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗲𝘃𝗲𝗿𝘆 𝗸𝗲𝘆 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝘀 𝗮 𝘁𝗲𝘀𝘁𝗮𝗯𝗹𝗲 𝗵𝘆𝗽𝗼𝘁𝗵𝗲𝘀𝗶𝘀. 𝗠𝗼𝘀𝘁 𝗱𝗲𝗲𝗽-𝘁𝗲𝗰𝗵 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝗳𝗮𝗶𝗹 𝗻𝗼𝘁 𝗳𝗼𝗿 𝗹𝗮𝗰𝗸 𝗼𝗳 𝘀𝗰𝗶𝗲𝗻𝗰𝗲, 𝗯𝘂𝘁 𝗳𝗼𝗿 𝗽𝗼𝗼𝗿 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗶𝗻𝗴.

Our Partner Luigi Negri has written a new book, “𝘋𝘦‑𝘙𝘪𝘴𝘬𝘪𝘯𝘨 𝘐𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵𝘴 𝘪𝘯 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘛𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯”, with Obloo Managing Partner Nicola Redi contributing the investment and valuation lens.

The book focuses on MedTech, but the message extends to any deep-tech startup: apply the scientific method outside the lab, to any key business decision.
→ treat every strategic decision as a hypothesis to test, not a belief to defend;
→ decide which assumption you de‑risk next (product readiness, stakeholder fit, financial viability…);
→ keep a “grip on reality”: update the plan when data contradict the story, not the other way round.

At Obloo, this is how we already work with founders across aerospace, robotics, energy and computational science founders: we fund the technology and we help build the decision‑making discipline around it.

More to come on this work, which will be released by Springer in April. Check upcoming events here: https://lnkd.in/dFx_DyA6

#deepscover